Cargando…

Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist

OBJECTIVE: The aim was to evaluate the cost-effectiveness of Crohn’s disease (CD) treatment with vedolizumab and ustekinumab after failure of therapy with tumor necrosis factor-α antagonists (anti-TNFs). METHODS: The Markov model incorporated the lifetime horizon, synthesis-based estimates of biolog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holko, Przemysław, Kawalec, Paweł, Pilc, Andrzej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999163/ https://www.ncbi.nlm.nih.gov/pubmed/29667146 http://dx.doi.org/10.1007/s40273-018-0653-2

Ejemplares similares

Health-Related Quality of Life Impairment and Indirect Cost of Crohn’s Disease: A Self-Report Study in Poland
por: Holko, Przemysław, et al.
Publicado: (2016)

Impact of Biologic Treatment of Crohn’s Disease on the Rate of Surgeries and Other Healthcare Resources: An Analysis of a Nationwide Database From Poland
por: Holko, Przemysław, et al.
Publicado: (2018)

Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis
por: Moćko, Paweł, et al.
Publicado: (2016)

Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2013)

Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis
por: Kawalec, P., et al.
Publicado: (2017)

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2012)

Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2018)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
por: Liu, Eddie Y., et al.
Publicado: (2017)

Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn’s Disease Patients
por: Gebeyehu, Gerum Gashaw, et al.
Publicado: (2022)

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
por: Bohm, Matthew, et al.
Publicado: (2020)

Cost effectiveness and cost utility of the noncoding blood glucose meter CONTOUR(®) TS
por: Holko, Przemyslaw, et al.
Publicado: (2011)

Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Cost-utility analysis of Ruconest(®) (conestat alfa) compared to Berinert(®) P (human C1 esterase inhibitor) in the treatment of acute, life-threatening angioedema attacks in patients with hereditary angioedema
por: Kawalec, Paweł, et al.
Publicado: (2013)

Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
por: Newman, Kira L., et al.
Publicado: (2023)

Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study)
por: Alrashed, Fatema, et al.
Publicado: (2023)

A Comment on Craig et al.: ‘‘Retigabine for the Adjunctive Treatment of Adults with Partial-Onset Seizures in Epilepsy with and without Secondary Generalization: A NICE Single Technology Appraisal’’
por: Holko, Przemysław, et al.
Publicado: (2013)

Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with vedolizumab or ustekinumab: findings from SOJOURN
por: Vu, Michelle, et al.
Publicado: (2023)

Disease activity, quality of life and indirect costs of psoriatic arthritis in Poland
por: Kawalec, Paweł, et al.
Publicado: (2016)

Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland
por: Stawowczyk, Ewa, et al.
Publicado: (2016)

Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland
por: Stawowczyk, Ewa, et al.
Publicado: (2016)

Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease
por: Kumar, Anand, et al.
Publicado: (2020)

Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease
por: Gisbert, Javier P., et al.
Publicado: (2023)

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
por: Shim, Hang Hock, et al.
Publicado: (2018)

Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis
por: Lukin, Dana, et al.
Publicado: (2020)

Disease activity, quality of life, and indirect costs of ulcerative colitis in Poland
por: Kawalec, Paweł, et al.
Publicado: (2017)

Cost of Refractory Crohn’s Disease Before and After Ustekinumab Utilization
por: Rahme, Elham, et al.
Publicado: (2019)

Indirect Costs of Inflammatory Bowel Diseases: A Comparison of Patient-Reported Outcomes Across 12 European Countries
por: Holko, Przemysław, et al.
Publicado: (2022)

Adalimumab/ustekinumab/vedolizumab: COVID-19 infection: 7 case reports
Publicado: (2022)

Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease
por: Schneider, Anna-Maria, et al.
Publicado: (2018)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Cassandra, Rayer, et al.
Publicado: (2022)

Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
por: Hansson-Hedblom, Amanda, et al.
Publicado: (2018)

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
por: Choi, Myeong Geun, et al.
Publicado: (2022)

Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
por: Lutz, Megan, et al.
Publicado: (2023)

Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Rayer, Cassandra, et al.
Publicado: (2023)

Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
por: Albshesh, Ahmad, et al.
Publicado: (2023)

Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China
por: Zhou, Ting, et al.
Publicado: (2021)

Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis
por: Krawczyk, Kinga, et al.
Publicado: (2023)

Vedolizumab in the treatment of Crohn’s disease of the pouch
por: Khan, Freeha, et al.
Publicado: (2018)

Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases
por: Singh, Siddharth, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gs9u1ug3r2h51i8ictam8las6j